CICLOPIROX CICLOPIROX BRYANT RANCH PREPACK FDA Approved Ciclopirox Gel, 0.77% contains a synthetic antifungal agent, ciclopirox. It is intended for topical dermatologic use only. Each gram of Ciclopirox Gel, 0.77% contains 7.70 mg of ciclopirox in a gel consisting of Purified Water USP, Isopropyl Alcohol USP, Octyldodecanol NF, Dimethicone Copolyol 190, Carbomer 980, Sodium Hydroxide NF, and Docusate Sodium USP. Ciclopirox Gel, 0.77% is a white, slightly fluid gel. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )- pyridinone, with the empirical formula C 12 H 17 NO 2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:
Generic: CICLOPIROX
Mfr: BRYANT RANCH PREPACK FDA Rx Only
FunFoxMeds box
Substance Ciclopirox
Route
TOPICAL
Applications
ANDA078266

Drug Facts

Composition & Profile

Strengths
0.77 % 30 g 45 g 100 g
Treats Conditions
Indications And Usage Superficial Dermatophyte Infections Ciclopirox Gel 0 77 Is Indicated For The Topical Treatment Of Interdigital Tinea Pedis And Tinea Corporis Due To Trichophyton Rubrum Trichophyton Mentagrophytes Or Epidermophyton Floccosum Seborrheic Dermatitis Ciclopirox Gel 0 77 Is Indicated For The Topical Treatment Of Seborrheic Dermatitis Of The Scalp
Pill Appearance
Color: white

Identifiers & Packaging

Container Type UNKNOWN
UNII
19W019ZDRJ
Packaging

HOW SUPPLIED Ciclopirox Gel, 0.77% NDC: 72162-1126-3: 30 g in a TUBE NDC: 72162-1126-2: 45 g in a TUBE NDC: 72162-1126-1: 100 g in a TUBE Store at 20°–25°C (68°–77°F) [see USP Controlled Room Temperature]. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504; Ciclopirox 0.77% Gel, #30 Label

Package Descriptions
  • HOW SUPPLIED Ciclopirox Gel, 0.77% NDC: 72162-1126-3: 30 g in a TUBE NDC: 72162-1126-2: 45 g in a TUBE NDC: 72162-1126-1: 100 g in a TUBE Store at 20°–25°C (68°–77°F) [see USP Controlled Room Temperature]. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
  • Ciclopirox 0.77% Gel, #30 Label

Overview

Ciclopirox Gel, 0.77% contains a synthetic antifungal agent, ciclopirox. It is intended for topical dermatologic use only. Each gram of Ciclopirox Gel, 0.77% contains 7.70 mg of ciclopirox in a gel consisting of Purified Water USP, Isopropyl Alcohol USP, Octyldodecanol NF, Dimethicone Copolyol 190, Carbomer 980, Sodium Hydroxide NF, and Docusate Sodium USP. Ciclopirox Gel, 0.77% is a white, slightly fluid gel. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )- pyridinone, with the empirical formula C 12 H 17 NO 2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:

Indications & Usage

Superficial Dermatophyte Infections Ciclopirox Gel, 0.77% is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum . Seborrheic Dermatitis Ciclopirox Gel, 0.77% is indicated for the topical treatment of seborrheic dermatitis of the scalp.

Dosage & Administration

Superficial Dermatophyte Infections Gently massage Ciclopirox Gel, 0.77% into the affected areas and surrounding skin twice daily, in the morning and evening immediately after cleaning or washing the areas to be treated. Interdigital tinea pedis and tinea corporis should be treated for 4 weeks. If a patient shows no clinical improvement after 4 weeks of treatment, the diagnosis should be reviewed. Seborrheic Dermatitis of the Scalp Apply Ciclopirox Gel, 0.77% to affected scalp areas twice daily, in the morning and evening for 4 weeks. Clinical improvement usually occurs within the first week with continuing resolution of signs and symptoms through the fourth week of treatment. If a patient shows no clinical improvement after 4 weeks of treatment, the diagnosis should be reviewed.

Warnings & Precautions
WARNINGS Ciclopirox Gel, 0.77% is not for ophthalmic, oral, or intravaginal use. Keep out of reach of children.
Contraindications

Ciclopirox Gel, 0.77% is contraindicated in individuals who have shown hypersensitivity to any of its components.

Adverse Reactions

In clinical trials, 140 (39%) of 359 subjects treated with Ciclopirox Gel, 0.77% reported adverse experiences, irrespective of relationship to test materials, which resulted in 8 subjects discontinuing treatment. The most frequent experience reported was skin burning sensation upon application, which occurred in approximately 34% of seborrheic dermatitis patients and 7% of tinea pedis patients. Adverse experiences occurring between 1% to 5% were contact dermatitis and pruritus. Other reactions that occurred in less than 1% included dry skin, acne, rash, alopecia, pain upon application, eye pain, and facial edema.


Similar Drugs

Related medications based on brand, generic name, substance, active ingredients.

View all similar drugs →